Invasive Fungal Infections Among Patients with Hematological Malignancies: A Two-Year Multicentric Study from Tehran, Iran

Davod Sheikh-Hoseini,Saeed Soleiman-Meigooni,Hassan Jalaeikhoo,Jalil Rajabi,Mohammad Hassan Kazemi-Galougahi,Taher Azimi,Ali Asgari

DOI: https://doi.org/10.5812/jjm-144500

2024-05-13

Jundishapur Journal of Microbiology

Abstract:Invasive Fungal Disease Hematological Malignancy Neutropenia Aspergillus Candida

microbiology

What problem does this paper attempt to address?

Clinical Characteristics of Patients with Hematologic Malignancies and Invasive Aspergillosis: A Cross-Sectional Clinical Report from Iran

Mohammadreza Salehi,Nafiseh Shahrbaf,Farhad Shahi,Sadegh Khodavaisy,Seyed Ali Dehghan Manshadi,Zahra Rafat,Kamran Roudini,Maryam Nakhostin,Hasti Kamali Sarvestani

DOI: https://doi.org/10.5812/jjm-142306

2024-02-10

Jundishapur Journal of Microbiology

Abstract:Invasive Aspergillosis Hematologic Malignancy Leukemia Invasive Fungal Infection Iran

microbiology
Invasive fungal infections in hematologic malignancies: Incidence, management, and antifungal therapy

Mohsen Meidani,Fatemeh Shafiee,Rasool Soltani

DOI: https://doi.org/10.4103/jrms.jrms_1072_21

2024-05-24

Journal of Research in Medical Sciences

Abstract:There are many types of hematologic malignancies (HMs), each with its own control and management methods. However, conventional chemotherapeutic agents and novel therapeutic strategies such as hematopoietic stem cell transplantation (HSCT) are the most common treatments for a variety of these disorders, [ 1 ] leading to improvement of the patient outcome. [ 2 ] Unfortunately, different infections including viral, bacterial, and fungal infections can make the health status of these patients more complicated. Fungal infections are the fourth most important health-related issue in the world and millions of people experience these life-threatening infections around the world. [ 3 ] Invasive fungal infections (IFIs) are among the most serious conditions in HM patients and one of the leading causes of morbidity and mortality in them. [ 4 ] In addition, IFIs are an important factor in increasing the cost of controlling and management of HMs. [ 5 ] In the last 20 years, the treatment of fungal infections has evolved substantially leading to the reduction of morbidity and mortality due to IFIs if the treatment is properly provided. [ 6 ] However, the number of people at high risk for IFIs has also increased substantially along with the elevated cost of treatment resulting from the longer duration of hospitalization and the resistance to routine antifungal drugs among causative pathogens. [ 7-10 ] In the US, for example, the hospitalization costs due to the invasive candidiasis and aspergillosis, as the two most important IFIs, have been estimated about 218 and 630 million dollars, respectively. [ 6 ] Therefore, timely diagnosis and effective prophylactic and therapeutic measures are mandatory.

medicine, general & internal
Efficacy and Safety of Itraconazole on Invasive Fungal Infections in 66 Patients with Malignant Hematological Diseases

XU Gai-xiang,QIAN Wen-bin,XIE Ya-ping,MAO Li-ping,MENG Hai-tao,MAI Wen-yuan,TONG Hong-yan,JIN Jie

DOI: https://doi.org/10.3321/j.issn:1003-3734.2009.04.012

2009-01-01

Abstract:Objective:To investigate the efficacy and safety of itraconazole on invasive fungal infections in patients with malignant hematological diseases. Methods: Sixty-six patients with malignant hematological diseases, who were diagnosed as invasive fungal infection, were retrospectively analyzed. The patients were treated with itraconazole as long as diagnosed. Results: ① The total effective rate was 59.1%, including 6.1% of cure rate and 53.0% of significantly improved-rate. The effective rates were 75.0%, 67.7% and 31.2% in the patients with confirmed diagnosis, clinical diagnosis and recommended diagnosis, respectively. The rates were 72.2% and 43.3% in the patients with and without detected fungi, respectively. ② The side-effect rate was 15.2%. ③ The effective rate was better in the patients with major imaging signs than in those with secondary imaging signs. ④ Of 33 patients who failed to the therapy of fluconazole, 19 patients were still sensitive to itroconazole. Conclusion: Itraconazole is effective and safe in the treatment of invasive fungal infections in patienus with hematological malignancy. However, the hepatic and renal functions should be tested regularly during the use of itraconazole.
Efficacy and Safety of Itraconazole As Empirical Antifungal Therapy in Febrile Neutropenic Patients with Hematologic Malignancies: an Open-Lable, Multicenter, Observational Trial in A Chinese Cohort

Cheng Shu,Zhou Jian-feng,Zou Ping,Huang Xiao-jun,Jin Jie,Shen Zhi-xiang

DOI: https://doi.org/10.3760/cma.j.issn.0366-6999.2011.22.013

2011-01-01

Abstract:Background Invasive fungal infection (IFI) is a common and fatal complication in neutropenic patients with hematological malignancy. Empirical antifungal therapy is widely used in practice due to the difficulty of pathogens determination and illness of the hosts. The aim of this study was to evaluate the efficacy and safety of itraconazole as empirical antifungal therapy for persistent fever in neutropenic patients with hematologic malignancies.Methods Two hundred and seventy-four patients with hematologic malignancies who had suspected fungal infections were enrolled in 18 centers across China between April 2008 and April 2009. Empirical antifungal therapy with intravenous itraconazole 200 mg twice daily was given for the first two days, followed by 200 mg once daily for the next 12 days. Oral itraconazole solution was sequential for follow-up therapy if necessary. Five composite end points were evaluated for the response, which was more restrictive and adopted for the first time in such study in China.Results The intent-to-treat analysis included data from 274 patients (full analysis set, FAS), of whom 248 were included as the per-protocol population (PPS). As the composite end point of five indices was concerned, the overall response rate was 43.4%. Seperately, defervescence was achieved in 90% of patients in which 55.5% occured during neutropenia. The mean time to defervescence was 2.71 days. Absence of breakthrough IFI during drug administration or within the first 7 days after study completion was observed in 71.5% of patients. Fifty-five point five percent patients with IFI at baseline was successfully treated. Ninety point five percent patients survived for at least 7 days after completing the study. PPS analysis revealed that the duration of neutropenia >= 10 days was a statistically significant negative predictor for the response. The withdrawal rate due to drug-related toxicity or lack of efficacy was 11.0%. The incidence of adverse events was 22.6%, in which 11.6% was study drug related. The most frequent adverse events were mild to moderate liver toxicity.Conclusion ltraconazole shows desirable efficacy and safety as empirical antifungal therapy for febrile neutropenic patients with hematologic malignancies. Chin Med J 2011;124(22):3670-3675
Invasive fungal infections in patients with acute leukemia: A retrospective cohort study at a tertiary-care hospital

Asli Alkan,Yahya Buyukasik,Omrum Uzun,Ahmet Ugur Demir,Lutfi Coplu

DOI: https://doi.org/10.1097/md.0000000000039959

IF: 1.6

2024-10-09

Medicine

Abstract:Invasive fungal infection (IFI) is a significant contributor to morbidity and mortality in patients with hematological malignancies and often develops as a result of disruption of host defense mechanisms. [ 1 ] In recent years, there has been an increase in the prevalence of IFI worldwide, largely attributed to the extended survival of acute leukemia patients by new treatment modalities and effective supportive care as well as to the advances in diagnostic methods. [ 2–4 ] In a study in which autopsy-proven IFI in patients with hematological malignancies were evaluated, IFI were identified in 31% of all autopsies, and the prevalence of invasive mold infections had increased significantly. [ 5 ] A review of autopsy studies showed that invasive aspergillosis is 1 of the most commonly overlooked diagnosis, and only about half of all IFI is diagnosed premortem. [ 6 ] On the other hand, the spectrum of infectious fungal pathogens has changed in the last few decades. [ 7 , 8 ] Timely and accurate detection of these infections is essential for a better outcome.

medicine, general & internal
Epidemiology, species distribution, antifungal susceptibility, and outcome of candidemia in intensive care units in Isfahan, Iran

Azam Haghighatfard,Saeed Abbasi,Pegah Alijani,Farzaneh Afyooni Akbari,Hossein Rashidi,Parvin Dehghan

DOI: https://doi.org/10.18502/cmm.8.3.11217

2022-11-27

Current Medical Mycology

Abstract:Background and Purpose: Candidemia is known as an invasive fungal infection with high mortality. The prevalence of candidemia in intensive care unit (ICU) patients is more than in other hospital wards. Early diagnosis of candidemia in these patients is essential for disease management. Materials and Methods: This study included 250 patients suspected of candidemia. Blood samples were taken from patients and incubated. The fungal isolates were identified by PCR-RFLP method using MSP I restriction enzyme. Demographic characteristics, risk factors, underlying diseases, and laboratory analysis results were mined in this study. Results: In total, 22 blood samples were identified as positive for Candida yeasts in culture. The most common underlying diseases in these patients were heart disease and hypertension (36.4%). Candida albicans with 12 cases (54.5%) was the most isolated species, followed by C. parapsilosis (n=5, 22.7%), C. glabrata (n=4, 18.2%), and C. tropicalis (n=1, 4.5%) in descending order. Intravenous catheter use was recognized as the most common risk factor in patients with candidemia (77.3%), and after that, the use of mechanical ventilation (68.2%) and urinary catheter (40.9%) obtained the highest frequency. Furthermore, 17 patients were prescribed at least one antifungal drug, of which fluconazole was the most used (36.4%). The mortality rate in patients in this study was 63.6%. All C. albicans isolates were susceptible to antifungal agents but in non-albicans Candida (NAC), drug resistance to fluconazole, voriconazole, and caspofungin were observed. Conclusion: Although C. albicans was the most common fungal species in this study, the prevalence of NAC species was high. The increasing frequency of NAC species is a concern because they have different patterns of drug resistance. Recognition of risk factors in patients admitted to ICUs can help prevent candidemia or properly manage the disease.
Survival Dynamics of Invasive Fungal Diseases in Pediatric Hemato-Oncology Patients at a Tertiary Medical Facility in Mexico from July 2020 to July 2023

Ariana Ordoñez V,Miguel Minero H,Javier Ordoñez,Itzel Villanueva G,Alfredo R Morayta

DOI: https://doi.org/10.1093/jpids/piae093.077

2024-11-04

Journal of the Pediatric Infectious Diseases Society

Abstract:BackgroundInvasive fungal diseases (IFD) have been increasing in prevalence over the past two decades, with filamentous fungi being the most common cause. However, candidiasis remains the predominant etiology of infection, especially in cases of neutropenic fever accompanied by neutropenic colitis. The prevalence of infections caused by Aspergillus species, Mucor species, Fusarium, and other species is higher among individuals with severe and extended neutropenia and those who have undergone hematopoietic progenitor cell transplantation.MethodsA retrospective, descriptive, observational study was conducted to identify cases of patients diagnosed with invasive fungal diseases, categorizing them as possible, probable, or confirmed. In our comprehensive analysis of cases, we prioritize the examination of diseases induced by filamentous fungi, while considering the specific chemotherapy regimen administered and the particular oncological condition.ResultsThe predominant etiology observed was invasive aspergillosis, followed by mucormycosis. A total of 18 cases suggestive of invasive Aspergillosis were identified, but clinical or histopathological investigations were not conducted due to limitations. The majority of cases were pulmonary, accounting for 92% of cases, while rhinosinusal involvement was identified in 8%. Factors such as clinical characteristics, imaging studies, serum galactomannan determination, and microbiological culture were considered. The patient survival rate was found to be 86.7%, with an average treatment duration of six weeks. A mortality rate of 3.7% was observed due to the underlying disease during the consolidation phase of invasive fungal diseases.ConclusionIn our study, invasive aspergillosis emerged as the predominant invasive fungal disease in pediatric hemato-oncology patients. Despite challenges in conducting comprehensive investigations, our findings underscore the importance of timely diagnosis and management. The 86.7% survival rate reflects the efficacy of the treatment approach employed, while the observed mortality emphasizes the impact of underlying diseases on outcomes. This study contributes valuable insights to the understanding and improvement of survival dynamics in pediatric patients facing invasive fungal diseases.

pediatrics,infectious diseases
Prevalence and molecular identification of protozoan intestinal parasitic infections in cancer patients and a control group

Leyla Bahadorizadeh,Khadijeh Khanaliha,Saeede Ghorbandoust,Farah Bokharei-Salim,Sara Minaeian,Nastaran Khodakarim,Marzieh Ghalamkari,Borna Salemi

DOI: https://doi.org/10.1186/s12879-024-10235-0

IF: 3.7

2024-11-28

BMC Infectious Diseases

Abstract:Parasitic infections, especially opportunistic infections, are important issues for immunocompromised patients, including cancer patients. In this study, the prevalence of intestinal protozoan infections was investigated in Iranian cancer patients and a control group using microscopic and molecular methods.

infectious diseases
Invasive Fungal Infection in Hematopoietic Stem Cell Transplant Recipient from an Indian Oncology Setting

Abdul Ghafur,Bikram Das,T Raja,Jose Easow,Radhika Kartikeyan,Benjamin M Easow,S G Ramanan

DOI: https://doi.org/10.1055/s-0043-57044

2023-08-02

Abstract:Abdul GhafurObjective Invasive fungal infections (IFI) are one of the major causes of morbidity and mortality in post-hematopoietic stem cell transplant (HSCT) recipients. Data from India is limited. The objective of this study was to analyze the incidence, risk factors, and outcomes associated with IFI in our center. Materials and Methods Adult patients, who underwent marrow/stem cell transplantation between 2014 and 2018, in an oncology center in India, were included in this single-center retrospective observational study. The revised European Organization for Research and Treatment of Cancer/ Mycoses Study Group (EORTC/MSG) consensus group 2008 definition for IFI was considered to define cases. Incidence, risk factors, and outcomes associated with IFI were analyzed. Statistical Analysis All continuous variables were represented by mean ± standard deviation and categorical variables as percentage. Comparison of categorical variables was done by either the chi-squared test or Fisher's exact test. All " p " values less than 0.05 were considered statistically significant. Results Out of the 126 patients who underwent HSCT between January 2014 and December 2018, 56 (44.4%) patients had allo-HSCT, 64 (50.8%) had auto-HSCT, and 6 (4.8%) had haplo-identical HSCT. Eighty-three (63%) patients were male and 43 (34%) females, and 113 (83.9%) Asians and 13 (10.3%) Africans. Total 111 (88%) patients received myeloablative conditioning and 24 (19%) received total body irradiation. The hematological conditions were acute myeloid leukemia ( n = 23; 18.25%), acute lymphoblastic leukemia ( n = 16; 12.69%), chronic myeloid leukemia ( n = 4; 3.17%), Hodgkin lymphoma ( n = 17; 13.4%), non-Hodgkin lymphoma ( n = 11; 8.73%), myeloma ( n = 35; 27.7%), sickle cell disease ( n = 13; 10.31%), etc. Most patients received fluconazole (78; 61.9%) followed by micafungin (23; 18.25%), posaconazole (20; 15.87%), voriconazole (4; 3.17%), and liposomal amphotericin B (1; 0.79%) as antifungal prophylaxis. The overall rate of IFI (possible cases included) was auto-HSCT ( n = 5; 7.81%), and allo-HSCT ( n = 5; 8.92%). Among auto-HSCT, the IFI was proven = 0, probable n = 1 (1.5%), and possible n = 4 (6.25%) and among allo-HSCT the IFI was proven = 0, probable n = 2 (3.57%), and possible n = 3 (5.35%). No patients in haplo-HSCT had IFI. The 1-year survival rate among the IFI cases was 8/10(80%). A meaningful comparison of the risk factors and the impact of prophylactic regimens were difficult because of the very low number of IFI cases. Conclusion The overall rate of IFI in HSCT patients in our setting was low compared to global data on IFI in HSCT.
Invasive fungal infections in patients with haematological malignancies at the University Hospital of Reunion Island (2018–2022): An observational study

Camille Estagnasié,Catherine Mohr,Laure Kamus,Patricia Zunic,Emmanuel Chirpaz,Marie-Pierre Moiton,Marie Lagrange-Xelot

DOI: https://doi.org/10.1093/mmy/myae102

IF: 3.747

2024-11-04

Medical Mycology

Abstract:Invasive fungal infections are a serious complication for haematology patients. However, there is no study on this subject in Reunion Island. The aim of this study was to estimate the incidence of invasive fungal infections in patients with haematological malignancies at the University Hospital of Reunion Island. We conducted a descriptive and ambispective study. We included any patient with haematological malignancy presenting with a putative, possible, probable, or proven invasive fungal infection, defined as per the criteria of the European Organisation for Research and Treatment of Cancer/Mycoses Study Group 2019, from January 2018 to December 2022. Data were collected from medical records and identified by ICD-10 coding and laboratory data. Eighty-nine invasive fungal infections were diagnosed in 76 patients. The 5-year incidence rate of invasive fungal infections was 1.7 per 100 person-years (95% Confidence Interval (CI) 1.3–2). Invasive aspergillosis was the most common infection (35/89, 39%), followed by invasive candidiasis (33/89, 37%), mucormycosis (7/89, 8%), and pneumocystosis (7/89, 8%). Most infections occurred in patients with acute myeloid leukaemia (32/89, 36%) and lymphoma (26/89, 29%). Six-month mortality was higher for mucormycosis (71%) than for aspergillosis (34%) and invasive candidiasis (33%). The incidence and distribution of fungal infections in haematology patients were similar to European cohorts, albeit with more mucormycosis, less pneumocystis, and a high proportion of Candida parapsilosis in candidemia.

infectious diseases,veterinary sciences,mycology
Hospital and post-discharge mortality in COVID-19 patients with a preexisting cancer diagnosis in Iran

Monireh Sadat Seyyedsalehi,Marveh Rahmati,Reza Ghalehtaki,Azin Nahvijou,Bita Eslami,Zoha Shaka,Seyed Farshad Allameh,Kazem Zendehdel

DOI: https://doi.org/10.1186/s12885-024-12663-2

IF: 4.638

2024-09-04

BMC Cancer

Abstract:Despite the severe impact of COVID-19 on cancer patients, data on COVID-19 outcomes in cancer patients from low- and middle-income countries is limited. We conducted a large study about the mortality rate of COVID-19 in cancer patients in Iran.

oncology
Invasive fungal infections in children with leukemia in a tertiary hospital in Oman: An eight-year review

Hind Al Hajri,Widad Al-Salmi,Karima Al Hinai,Saif Al-Housni,Ahmed Al-Harrasi,Hilal Al Hashami,Abdullah M S Al-Hatmi

DOI: https://doi.org/10.22034/CMM.2023.345108.1447

Abstract:Background and purpose: Invasive fungal disease (IFD) is a common and serious consequence of leukemia in children and the incidence of these infections has increased due to chemotherapy. This study aimed to present the epidemiology of IFD in a cohort of children with leukemia from a tertiary reference institution in Oman. Materials and methods: A retrospective study of IFDs in pediatric patients below 13 years of age with newly diagnosed or relapsed leukemia was conducted at the Royal Hospital in Muscat, Oman. From 2010 to 2017, IFD episodes in children with leukemia were evaluated retrospectively, considering age, gender, type of leukemia, chemotherapy regimen, IFD detection phase, neutropenia, prevention, diagnostic method, and treatment. Results: Between 2010 and 2017, 198 children with leukemia were admitted and treated at Royal Hospital. Invasive fungal infection (IFI) was diagnosed in 32 patients out of 198 (16.1%), and IFI was defined as probable and proven in 53% (n=17) and 47% (n=15) of the cases, respectively. At 1.1:1, the male-to-female ratio was roughly equal. According to chest computed tomography scans, 65.6% of patients had radiological features of fungal infections. Positive fungal cultures were found in the bronchoalveolar lavage of three patients, 37.5% of whom had positive blood cultures, and 3% had positive urine cultures as a neonatal invasive candidiasis. In three patients, invasive aspergillosis caused pulmonary IFD, accounting for 9.3% of all infection sites. Candidaemia was found in 28% of IFD patients, and the most common organism was Candida tropicalis (15.6%), followed by Candida parapsilosis (6.25%). Furthermore, the major risk factor was febrile neutropenia. Conclusion: In children with leukemia, invasive fungal infection is common and serious. Despite aggressive treatment, mortality among these high-risk patients remains high.
P210 Fungal isolates of the respiratory tract in symptomatic patients hospitalized in pulmonary units: A mycological and molecular epidemiologic study

Seyed Jamal Hashemi

DOI: https://doi.org/10.1093/mmy/myac072.P210

IF: 3.747

2022-09-22

Medical Mycology

Abstract:Poster session 2, September 22, 2022, 12:30 PM - 1:30 PMObjectiveFungal respiratory infections are being recognized with increasing frequency in parallel with an expanding population of immunocompromised patients. In most cases, colonization is the first step in the progression to pulmonary fungal infection. This study was designed to evaluate the distribution of fungal elements in the respiratory tract of symptomatic patients hospitalized in pulmonary units.MethodsThis descriptive cross-sectional study was carried out over a period of 2 years, from October 2017 to October 2019 in Guilan province, located in Iran's northern region. In the current study, bronchoalveolar lavage or sputum specimens were collected. All samples were analyzed by direct microscopy using KOH 10% and culture. Fungal identification was accomplished by internal transcribed spacer (ITS) and beta-tubulin sequencing. Also, in patients suspected of invasive pulmonary aspergillosis, BAL specimens were tested for galactomannan (GM) antigen.ResultsA total of 384 lung specimens [192 bronchoalveolar lavage (BAL) and 192 sputum samples] were obtained from symptomatic patients hospitalized in pulmonary units. Of these, 137 (35.67%) were positive in direct examination and culture. Among the 137 positive cases, most isolates were from male patients 86 (62.77%) and most of them were between 46 and 72 years. Candida albicans (37.22%) and C. tropicalis (21.89%) represent the two most commonly isolated species in the current study. Cough (94.16%), dyspnea (81.02%), purulent sputum (62.04%), and weight loss (56.2%) were the predominant symptoms and tuberculosis (24.81%), chemotherapy (21.89%), and diabetes mellitus (19.70%) were the predominant underlying conditions. Also, 5 cases of invasive pulmonary aspergillosis and 1 case of mucormycosis were diagnosed.Conclusion Candida albicans was the most common fungal species isolated from symptomatic patients hospitalized in pulmonary units. Tuberculosis, chemotherapy and diabetes mellitus were important underlying conditions for pulmonary fungal colonization and/or infection.

infectious diseases,veterinary sciences,mycology
Invasive fungal infection in patients receiving chemotherapy for hematological malignancy: a multicenter, prospective, observational study in China

Yuqian Sun,He Huang,Jing Chen,Jianyong Li,Jun Ma,Juan Li,Yingmin Liang,Jianmin Wang,Yan Li,Kang Yu,Jianda Hu,Jie Jin,Chun Wang,Depei Wu,Yang Xiao,Xiaojun Huang

DOI: https://doi.org/10.1007/s13277-014-2649-7

2014-01-01

Abstract:This stud y examined the epidemiology, risk factors, management, and outcome of invasive fungal infection (IFI) in patients receiving chemotherapy for hematological malignancy in China. IFI risk factors were analyzed using univariate analysis and multivariate logistic regression. In total, 4,192 patients receiving 4,889 chemotherapy courses were enrolled [mean age 40.7 years, 58.4 % male, 16.9 % children (<18 years)]. The most common hematological diseases were acute myeloid leukemia (AML, 28.5 %), non-Hodgkin lymphoma (NHL, 26.3 %), and acute lymphoblastic leukemia (ALL, 20.2 %). Severe neutropenia (absolute neutrophil count [ANC] <500/mm 3 ) occurred after one third (1,633/4,889, 33.4 %) of chemotherapy courses. Incidence of proven/probable IFI was 2.1 % per chemotherapy course and higher in patients with myelodysplastic syndrome (MDS, 4.94 %), acute hyperleukocytic leukemia (AHL, 4.76 %), AML (3.83 %), or induction chemotherapy. Risk factors included ANC <500/mm 3 [odds ratio (OR) 3.60], AML or MDS (OR 1.97), induction chemotherapy (OR 2.58), previous IFI (OR 3.08), and being male (OR 1.74). Antifungal agents, prescribed in one quarter (1,211/4,889, 24.8 %) of chemotherapy courses, included primary/secondary prophylaxis ( n = 827, 16.9 %) and/or treatment ( n = 655, 13.4 %; 86.9 % triazoles), which was empirical (84.3 %), pre-emptive (8.6 %), or targeted (7.1 %). Overall mortality following each chemotherapy course (1.5 %) increased in proven/probable (11.7 %) and possible IFI (8.2 %). In summary, IFI was more common in MDS, AHL, AML, or induction chemotherapy, and substantially increased mortality. Neutropenic patients receiving induction chemotherapy for AML or MDS and those with previous IFI were at particular risk. Antifungal prophylaxis showed an independent protective effect but was not commonly used, even in high-risk patients. By contrast, empiric antifungals were widely used.
Invasive Fungal Infections of the Head and Neck: A Tertiary Hospital Experience

Tieying Hou,W. Robert Bell,Hector Mesa

DOI: https://doi.org/10.3390/pathogens13070530

IF: 3.7

2024-06-23

Pathogens

Abstract:From the existing millions of fungal species, only a few cause disease. In this study, we investigated invasive fungal infections in the head and neck (H&N) over a 19-year period (2005 to 2024) at a large academic healthcare system. Among the 413 documented fungal H&N infections, 336 were noninvasive, and 77 were invasive. The highest incidence of invasive infections occurred in the sinonasal cavities, with a 15-fold difference compared to other sites. Most infections affected adults over 40 years old. The most common organisms were Mucorales (51%), hyaline molds (29%), and Candida (11%). Risk factors included malignancy, transplant, diabetes, and illicit drug use. Mortality was high in patients with malignancy and/or transplant. Infections affecting the mandible were usually a complication of osteoradionecrosis and were associated with the coinfection of Candida and Actinomyces. At other sites, infections were rare and were usually the result of penetrating injuries or immunosuppression. Treatment typically involved a combination of antifungals and surgical procedures.

microbiology
[Candida Colonization and Invasive Fungal Infection in Hospitalized Patients with Hematological Malignancies].

Yue-yun Lai,Li Bao,Xi-jing Lu,Jin Lu,Jin Yu,Ruo-yu Li,Xiao-jun Huang

DOI: https://doi.org/10.3760/cma.j.issn.0376-2491.2009.04.006

2009-01-01

Abstract:OBJECTIVE:To investigate thee status of Candida colonization and the risk factors of invasive fungal infection (IFI) in hospitalized patients with hematological malignancies.METHODS:114 patients with hematological malignancies admitted to the hematology wards from May 2004 to April 2005 underwent fungal culture of their samples of urine, feces, and saliva once a week until the end of the sixth week of hospitalization or they were discharged. Culture of blood, sputum, or sterile body fluids were carried out when the patients were suspected to have IFI.RESULTS:165 strains of Candida spp. were isolated from 46 of the 114 patients, C. albicans accounting for 78.8% and non-albicans Candida for 21.2% respectively. Candida was found in 38 patients (33.3%) were found to have colonization of Candida, chiefly C. albicans (76.3%). The risk factors of Candida colonization included long duration of leucopenia (WBC < 0.5 x 10(9)/L for more than 10 days) and broad-spectrum antibiotic administration. Univariate analysis showed that the risk factors of IFI included Candida colonization, long duration of leucopenia, and administration of carbapenem antibiotics, and multivariate analysis showed that long duration of leucopenia (WBC < 0.5 x 10(9)/L for more than 10 days) was the only risk factor of IFI (P = 0.015).CONCLUSION:C. albicans is still the major organism isolated from the patients with hematological malignancies. Patients with hematological malignancies have a high incidence of Candida colonization. Long duration of leucopenia is the only risk factor for IFI.
Invasive Fungal Infections in Patients with Hematological Malignancies: Emergence of Resistant Pathogens and New Antifungal Therapies

Maria N Gamaletsou,Thomas J Walsh,Nikolaos V Sipsas

DOI: https://doi.org/10.4274/tjh.2018.0007

2018-03-01

Abstract:Invasive fungal infections caused by drug-resistant organisms are an emerging threat to heavily immunosuppressed patients with hematological malignancies. Modern early antifungal treatment strategies, such as prophylaxis and empirical and preemptive therapy, result in long-term exposure to antifungal agents, which is a major driving force for the development of resistance. The extended use of central venous catheters, the nonlinear pharmacokinetics of certain antifungal agents, neutropenia, other forms of intense immunosuppression, and drug toxicities are other contributing factors. The widespread use of agricultural and industrial fungicides with similar chemical structures and mechanisms of action has resulted in the development of environmental reservoirs for some drug-resistant fungi, especially azole-resistant Aspergillus species, which have been reported from four continents. The majority of resistant strains have the mutation TR34/L98H, a finding suggesting that the source of resistance is the environment. The global emergence of new fungal pathogens with inherent resistance, such as Candida auris, is a new public health threat. The most common mechanism of antifungal drug resistance is the induction of efflux pumps, which decrease intracellular drug concentrations. Overexpression, depletion, and alteration of the drug target are other mechanisms of resistance. Mutations in the ERG11 gene alter the protein structure of C-demethylase, reducing the efficacy of antifungal triazoles. Candida species become echinocandin-resistant by mutations in FKS genes. A shift in the epidemiology of Candida towards resistant non-albicans Candida spp. has emerged among patients with hematological malignancies. There is no definite association between antifungal resistance, as defined by elevated minimum inhibitory concentrations, and clinical outcomes in this population. Detection of genes or mutations conferring resistance with the use of molecular methods may offer better predictive values in certain cases. Treatment options for resistant fungal infections are limited and new drugs with novel mechanisms of actions are needed. Prevention of resistance through antifungal stewardship programs is of paramount importance.
Fungal-associated pneumonia in patients with hematological malignancies

Sarai Pineda-Benítez,Beda D Islas-Muñoz,Pamela Alatorre-Fernández,Cyntia Ibanes-Gutiérrez C,Patricia Volkow-Fernández,Patricia Cornejo-Juárez

DOI: https://doi.org/10.1016/j.ijmmb.2024.100654

Abstract:Purpose: Patients with hematologic malignancies (HM) are at high risk of invasive lung fungal infections (ILFI). To describe the main characteristics, treatment, and outcomes for five years in adult patients with HM and fungal pneumonia. Methods: We conducted a retrospective study at Instituto Nacional de Cancerología (INCan), a referral tertiary care oncology hospital with 135 beds in Mexico City, Mexico. We included all cases of fungal pneumonia in patients with HM from January 1, 2017, to December 31, 2022. Cases were classified as proven, probable, and possible according to EORTC/MSG criteria 2021. Results: Two hundred ten patients were included; the mean age was 40 years. The most frequent HM was acute lymphoblastic leukemia (n = 74) and acute myeloid leukemia (n = 68). One hundred forty patients (66.7%) had severe neutropenia for a median of 16 days. All patients had a CT thorax scan; in 132 (62.9%), multiple nodules were documented. Serum galactomannan (GM) was positive in 21/192 (10.9%) and bronchoalveolar lavage in 9/36 (25%). Fifty-three patients (25.2%) died in the first month. In the multivariate analysis for mortality in the first 30 days, hypoalbuminemia, shock, possible ILFI, and inappropriate antifungal treatment were statistically associated. Conclusions: In high-risk HM patients, CT thorax scan and GM help diagnose ILFI. An appropriate antifungal improves mortality.
21-plex PCR and Antifungal Susceptibility Aspects of Fungemia Agents in Pediatric Patients with Hematological Malignancies: A Single-Center Experience

Ali Amin Asnafi,Maryam Moslem,Fatemeh Sarbandi,Sadegh Khodavaisy,Neda Kiasat

DOI: https://doi.org/10.5812/jjm-148274

2024-08-19

Jundishapur Journal of Microbiology

Abstract:Background: Fungemia is a life-threatening infection which requires an early diagnosis and use of appropriate antifungal agents to be treated effectively. Objectives: Here, we describe the clinical-epidemiological characteristics as well as the antifungal susceptibility patterns of fungal agents in pediatric patients with malignancy. Methods: Two hundred and five blood samples were cultured to detect infection. The infectious agents were identified by phenotypic methods and 21-plex PCR. Antifungal susceptibility testing was performed using an E-test and disc diffusion test based on CLSI standard M27-A3 protocol. The demographic data of the studied population were extracted and analyzed. Results: In total, 36 out of 205 patients (17.6%) were positive for fungemia. 32 (88.9%) and 4 (11.1%) cases were found to be caused by Candida and Rhodotorula species, respectively. The patient's age ranged from 1 to 14 years. The majority of the patients were males (28; 77.8%) and were hospitalized for more than seven days (33; 91.7%). Non-Candida albicans species were the most common agents of fungemia (27 patients; 75%), with C. parapsilosis (77.8 %) as the dominant agent. Fever, central venous catheters, and broad-spectrum antibiotic therapy were observed in all cases. Itraconazole resistance was observed in a species of C. orthopsilosis. While the Candida isolates were susceptible to fluconazole, C. parapsilosis showed a significant rate of resistance to caspofungin, followed by itraconazole and amphotericin B. Overall, no mortality was reported among the fungemia cases. Conclusions: This study identified acute lymphoblastic leukemia (ALL) as a hematologic malignancy associated with fungemia. The increase of non-C. albicans species, including C. parapsilosis, along with reduced susceptibility to antifungal drugs, maybe a warning sign in pediatric patients with malignancies. Furthermore, fluconazole was the most effective antifungal agent against the recovered isolates. Therefore, the best strategy for the management of fungemia is to increase knowledge based on local epidemiological and mycological characteristics.

microbiology
Oropharyngeal Candida Colonization in Patients with Acute Myeloid Leukemia

Shiva Shirazian,Soheila Manifar,Reza Safaei Nodehi,Mohaddeseh Shabani

DOI: https://doi.org/10.18502/fid.v17i1.3966

Abstract:Objectives: Oral candidiasis has increased in recent years because of the increasing number of high-risk populations. The prevalence of Candida species is different worldwide because of the difference between population characteristics, sampling protocols, and geographic regions. Therefore, determining the more prevalent Candida species in different geographic regions seems essential. This study aimed to determine the more prevalent Candida species in acute myeloid leukemia (AML) patients in comparison with healthy individuals in Iran in 2016. Materials and methods: Fifty-one patients with AML and 62 healthy controls participated in this cross-sectional study. Samples were collected using a swab rubbed softly on the dorsal surface of the tongue and the oropharynx. The samples were cultured on CHROMagar Candida for 2 to 4 days. For differentiation between albicans and non-albicans species, positive samples were linearly inoculated on Corn Meal Agar with Tween-80. Candida species were identified using a microscope. Data were analyzed using chi-square and Fisher's exact tests. Results: Candida colonization was more frequent in AML patients (41.2%) in comparison with healthy participants (38.7%). Candida glabrata (C. glabrata; 27.5%) and Candida albicans (C. albicans; 32.3%) were the most common isolated species in the AML patients and the controls, respectively. There was a significant decrease in the frequency of C. albicans (P=0.022) and a significant increase in the frequency of C. glabrata (P=0.002) in the AML patients in comparison with the controls. Conclusion: AML patients are more susceptible to candidiasis. C. glabrata is the dominant Candida species in AML patients.

Invasive Fungal Infections Among Patients with Hematological Malignancies: A Two-Year Multicentric Study from Tehran, Iran

Clinical Characteristics of Patients with Hematologic Malignancies and Invasive Aspergillosis: A Cross-Sectional Clinical Report from Iran

Invasive fungal infections in hematologic malignancies: Incidence, management, and antifungal therapy

Efficacy and Safety of Itraconazole on Invasive Fungal Infections in 66 Patients with Malignant Hematological Diseases

Efficacy and Safety of Itraconazole As Empirical Antifungal Therapy in Febrile Neutropenic Patients with Hematologic Malignancies: an Open-Lable, Multicenter, Observational Trial in A Chinese Cohort

Invasive fungal infections in patients with acute leukemia: A retrospective cohort study at a tertiary-care hospital

Epidemiology, species distribution, antifungal susceptibility, and outcome of candidemia in intensive care units in Isfahan, Iran

Survival Dynamics of Invasive Fungal Diseases in Pediatric Hemato-Oncology Patients at a Tertiary Medical Facility in Mexico from July 2020 to July 2023

Prevalence and molecular identification of protozoan intestinal parasitic infections in cancer patients and a control group

Invasive Fungal Infection in Hematopoietic Stem Cell Transplant Recipient from an Indian Oncology Setting

Invasive fungal infections in patients with haematological malignancies at the University Hospital of Reunion Island (2018–2022): An observational study

Hospital and post-discharge mortality in COVID-19 patients with a preexisting cancer diagnosis in Iran

Invasive fungal infections in children with leukemia in a tertiary hospital in Oman: An eight-year review

P210 Fungal isolates of the respiratory tract in symptomatic patients hospitalized in pulmonary units: A mycological and molecular epidemiologic study

Invasive fungal infection in patients receiving chemotherapy for hematological malignancy: a multicenter, prospective, observational study in China

Invasive Fungal Infections of the Head and Neck: A Tertiary Hospital Experience

[Candida Colonization and Invasive Fungal Infection in Hospitalized Patients with Hematological Malignancies].

Invasive Fungal Infections in Patients with Hematological Malignancies: Emergence of Resistant Pathogens and New Antifungal Therapies

Fungal-associated pneumonia in patients with hematological malignancies

21-plex PCR and Antifungal Susceptibility Aspects of Fungemia Agents in Pediatric Patients with Hematological Malignancies: A Single-Center Experience

Oropharyngeal Candida Colonization in Patients with Acute Myeloid Leukemia